Renal protection in the patients with idiopathic hypertensia: the possibilities of the combined blockade of the renin-angiotensin-aldosteron system
- Authors: Kachnov V.A1, Tyrenko V.V1, Nikitin A.E1, Sinopalnikov D.O1, Koltsov A.V1
-
Affiliations:
- Issue: Vol 331, No 8 (2010)
- Pages: 20-24
- Section: Articles
- URL: https://journals.eco-vector.com/0026-9050/article/view/75071
- DOI: https://doi.org/10.17816/RMMJ75071
- ID: 75071
Cite item
Open Access
Access granted
Abstract
Reninangiotensinaldosterone system is a key link in regulation of blood pressure and causes the target organ damage in hypertensive patients. For many years is not lost interest in the pharmacological blockade of RAAS in order to achieve target levels of BP and prevent damage target organs, particularly kidneys. Most recently recommended for clinical application of direct rennin inhibitor - aliskiren, a number of reseaeches have proven expressed nephroprotective effect. However, at present there is no unequivocal answer to the question whether there are advantages in combined RAAS blockade in hypertensive patients with use of aliskiren and angiotensinconverting enzyme inhibitor or angiotensin receptor blocker.
Full Text
References
- Чазова И.Е., Ратова Л.Г. Артериальная гипертония, курение, почки - что общего? // Справочник поликлинического врача. - 2008. - № 10. - С. 14-17.
- Шальнова С.А., Баланова Ю.А., Константинов В.В. и др. Артериальная гипертония: распространенность, осведомленность, прием антигипертензивных препаратов и эффективность лечения среди населения Российской Федерации // Рос. кардиол. журн. - 2006. - № 4. - С. 45-50.
- Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design // Nephrol. Dial. Transplant. - 2009, Jan. 14. [Epub ahead of print] 1 of 9.
- Boehm M., Nabel E.G. Angiotensin-Converting Enzyme 2 - A New Cardiac Regulator // N. Engl. J. Med. - 2002. - Vol. 347. - P. 1795-1797.
- Dogrell S.A. ACE inhibitors and AT-1-receptor antagonists COOPERATE in non-diabetic renal disease // Lancet. - 2003. -Vol. 361. - Р. 117-124.
- Goodfriend Т.Ь. Angiotensins: actions and receptors. In Hypertension S.Oparil, M.Weber. -2000. - P. 11-13.
- Joshi S.R. et al. Evaluation of efficacy and tolerability of Losartan and Ramipril combination in the management of hypertensive patients with associated diabetes mellitus in India (LORD Trial) // J. Assoc. Physicians India. - 2004. - Vol. 52. -P. 189-195.
- Mogensen C.E. et al. Randomised controlled trial of dual blockade of renin- angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study // Brit. Med. J. - 2000. - Vol. 321. - P. 1440-1444.
- Parving H.H., Persson F., Lewis J.B. et al. AVOID Study Investigators. Aliskiren combined with losartan in type 2 diabetes and nephropathy // N. Engl. J. Med. - 2008, Jun. 5. - Vol. 358, N 23. - Р. 2433-2446.
- Rene R. Role of Angiotensin-1-Receptor Blockers In Cardiorenal Disease // Current. Drug. Therapy. - 2006. - Vol. 1. - P. 47-54.
- Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors / Eduardo Pimenta and Suzanne Oparil // Vasc. Health Risk. Manag. - 2009. - N 5. - Р. 453-463.
- Yusuf S. et al. For the ONTARGET investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events // N. Engl. J. Med. - 2008. - Vol. 358. - Р. 1547-1559.
Supplementary files
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).